Enlivex $ENLV: Allocetra Phase 2b U.S. Enrollment Opens; Addressing 78 Million Patient Opportunity With No Competing Disease-Modifying Therapies Knee osteoarthritis is one of the most prevalent disabling conditions in the world, and it remains entirely without an approved disease-modifying treatment. Enlivex is now enrolling patients in the United States as part of its global Phase 2b trial of Allocetra™, an allogeneic, off-the-shelf cell therapy engineered to reprogram macrophages back toward their homeostatic state. The rationale for Allocetra™ is grounded in the current scientific understanding that disrupted macrophage function drives the chronic inflammation that underpins osteoarthritis progression — a mechanism distinct from everything currently in the standard-of-care toolkit. Key Investor Takeaways: • Unmet Need is Structural: 32 million Americans affected today, 78 million projected by 2040, and currently pain relief and surgery are the only tools available. • Six-Month Efficacy Data on the Horizon: Primary endpoints measure pain and physical function changes from baseline at three and six months post-treatment. • Clinical Momentum is Real: Positive Phase 1 & Phase 2a results in the same patient population • Platform Applicability: Positive Phase 2b data would support Allocetra's macrophage modulation potential across a broader range of inflammatory and autoimmune conditions. Read the full announcement: $ENLV $RAIN $MSTR $MARA $TSLA $SMLR $COIN $FORD $HIVE $EXOD $JNJ $ABBV $MRK